leupeptins and Cachexia

leupeptins has been researched along with Cachexia* in 2 studies

Other Studies

2 other study(ies) available for leupeptins and Cachexia

ArticleYear
MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia.
    Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:7

    To evaluate the effect of proteasome inhibitor MG132 in cancer cachexia and to delineate the molecular mechanism underlying.. We established an experimental cancer cachexia model by subcutaneously implanting colon 26 cells into the armpits of BALB/c mice. Following administration of MG132 at various time points, body weight, food intake, gastrocnemius muscle weight, spontaneous activity and survival of tumor-bearing mice were examined along with tumor growth. Moreover, cachectic markers including glucose, triglyceride, albumin and total proteins as well as levels of the proinflammatory cytokines TNF-α and IL-6 in serum and gastrocnemius tissue were measured. Finally, mRNA and protein levels of p65, IκBα, and ubiquitin E3 ligases MuRF1 and MAFbx in gastrocnemius muscle were assessed.. MG132 treatment significantly alleviated cancer cachexia as demonstrated by attenuated weight loss, altered carbohydrate metabolism and muscle atrophy and increased spontaneous activity and survival time of tumor-bearing mice. MG132 reduced tumor growth and the levels of TNF-α and IL-6 in serum and gastrocnemius tissue. NF-κB, MuRF1 and MAFbx were also inhibited by MG132. Unexpectedly, MG132 was more efficient when administrated during the early stages of cachexia. MG132 had no effect on food intake of tumor-bearing mice.. Our results demonstrate that MG132-induced inhibition of the ubiquitin-proteasome pathway in cancer cachexia decreased the activity of NF-κB and the degradation of IκBα, and reduced the levels of TNF-α and IL-6 in serum and gastrocnemius tissue, accompanied by downregulation of MuRF1 and MAFbx. These data suggest that MG132 is a potential therapeutic and preventive agent for cancer cachexia.

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cachexia; Carbohydrate Metabolism; Cell Line, Tumor; Interleukin-6; Leupeptins; Male; Mice; Mice, Inbred BALB C; Motor Activity; Muscle, Skeletal; Neoplasm Transplantation; NF-kappa B; Proteasome Inhibitors; Proteolysis; Tumor Burden; Tumor Necrosis Factor-alpha; Ubiquitination; Weight Loss

2013
Pharmacological interference with tissue hypercatabolism in tumour-bearing rats.
    The Biochemical journal, 1994, Apr-01, Volume: 299 ( Pt 1)

    Marked loss of body weight and profound waste of both skeletal muscle and white adipose tissue occur in rats into which the ascites hepatoma Yoshida AH-130 has been transplanted, associated with marked perturbations in the hormonal homoeostasis and the presence of circulating tumour necrosis factor and high plasma levels of prostaglandin E2 [Tessitore, Costelli and Baccino (1993) Br. J. Cancer 67, 15-23]. On the basis of previous findings, the present study examined whether the development of cachexia in this model system could be significantly affected by adrenalectomy or by pharmacological treatments that may interfere with proximal or distal mediators of tissue hypercatabolism. In no instance was tumour growth modified. Medroxyprogesterone acetate, an anabolic-hormone-like drug, was completely ineffective. In adrenalectomized animals, although changes such as the elevation of plasma triacylglycerols and corticosterone were corrected, the general course of cachexia was not modified. A partial prevention of muscle waste was observed with acetylsalicylic acid, a non-steroidal anti-inflammatory drug, or with leupeptin, a proteinase inhibitor. Insulin afforded the most significant preservation of muscle protein and adipose-tissue mass, which were maintained close to control values even 10 days after transplantation. The effects of insulin on gastrocnemius muscle and liver protein content were exerted by slowing down protein turnover, mainly enhancing synthesis. Consistently, the total free amino acid concentration in the gastrocnemius of insulin-treated rats 10 days after tumour transplantation was close to that of controls. Although treatment with insulin decreased plasma corticosterone to normal values, it did not modify the circulating level of tumour necrosis factor. On the whole these data show that it seems possible to prevent, at least in part, the tissue waste that characterizes cancer cachexia by purely pharmacological means.

    Topics: Adrenalectomy; Animals; Aspirin; Blood Glucose; Body Weight; Cachexia; Cathepsin D; Cholesterol; Endopeptidases; Hormones; Insulin; Leupeptins; Male; Medroxyprogesterone Acetate; Muscle Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Rats; Rats, Wistar; Triglycerides

1994